RedHill-Biopharma's-Opaganib-Inhibits-COVID-19-Variants-in-Preclinical Study
Mon, June 28, 2021, 7:00 AM
RDHL
Opaganib strongly inhibits Beta (South African) and Gamma (Brazilian) COVID-19 variants, further supporting its antiviral activity
Opaganib's unique, orally-administered, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is also expected to maintain effect against other emerging variants, including the Delta (Indian) variant
Completion of opaganib's global fully enrolled 475-patient Phase 2/3 study in hospitalized patients with COVID-19 expected in the coming weeks
TEL AVIV, Israel and RALEIGH, N.C., June 28, 2021 /PRNewswire/ -- Re
